peptide PVA: encoded by an RNA that is complementary to arginine vasopressin mRNA [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5748196 |
| MeSH ID | M0157721 |
| Synonym |
|---|
| 114472-81-0 |
| pva peptide |
| l-alanine, n-(n-(n-(n-(n-(n-(n-(n-l-seryl-l-seryl)-l-tryptophyl)-l-alanyl)-l-valyl)-l-leucyl)-l-alpha-glutamyl)-l-valyl)- |
| vasopressin antisense peptide |
| ser-ser-trp-ala-val-leu-glu-val-ala |
| peptide pva |
| DTXSID30150744 |
| (2s,5s,8s,11s,14s,17s,20s,23s,26s)-20-((1h-indol-3-yl)methyl)-26-amino-8-(2-carboxyethyl)-27-hydroxy-23-(hydroxymethyl)-11-isobutyl-5,14-diisopropyl-2,17-dimethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazaheptacosanoic acid |
| (4s)-4-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2s)-1-[[(1s)-1-carboxyethyl]amin |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.78) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||